EGFR and cancer: Taken together, these findings suggest that (i) there is a high level of EGFR pathway activation heterogeneity in both cancerous and normal tissues; (ii) in cancers, this heterogeneity cannot, for the most part, be explained by their intrinsic properties like the presence of clinically relevant mutations of EGFR pathway components.